Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.
Date
2011Author
Saip, P.
Icli, F.
Altundag, K.
Coskun, U.
Paydas, S.
Basaran, G.
Dogu, G. G.
Eralp, Y.
Uslu, R.
Sevinc, A.
Onur, H.
Mandel, N. M.
Sezgin, C.
Altinbas, M.
Guler, N.
Isikdogan, A.
Gokmen, E.
Uygun, K.
Ustuner, Z.
Yaren, A.
Metadata
Show full item recordCollections
- Makale [92796]